NC
IRON icon

nVerses Capital’s Disc Medicine IRON Stock Holding History

nVerses Capital’s Portfolio IRON Stock Details IRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-200
Closed -$9.01K – 1199
2024
Q2 		$9.01K Buy
+200
New +$6.8K 0.01% 909

Other funds holding IRON

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

nVerses Capital's IRON Position: Q3 2024 in Review

nVerses Capital sold out of Disc Medicine (IRON) in Q3 2024, closing a stake of 200 shares — an estimated $9.01K sold.

nVerses Capital first reported a position in IRON in Q2 2024 and held it in 1 quarter. The position peaked at $9.01K in Q2 2024. 132 funds tracked by Wall St. Rank hold IRON as of Q3 2024.

  • nVerses Capital reported no remaining Disc Medicine position as of Q3 2024 after selling out during the quarter.
  • nVerses Capital sold 200 Disc Medicine shares in Q3 2024, an estimated $9.01K.
  • nVerses Capital first reported a position in Disc Medicine in Q2 2024 and held it in 1 quarter.
  • nVerses Capital's Disc Medicine position peaked at $9.01K in Q2 2024.
  • 132 funds tracked by Wall St. Rank held Disc Medicine as of Q3 2024.

Based on nVerses Capital's 13F filing for Q3 2024, filed 16 Oct 2024.